Sorry, you need to enable JavaScript to visit this website.
Home About Responsibility Global Impact An Accord for a Healthier World

An Accord for a Healthier World

An Accord for a Healthier World aims to provide all of Pfizer’s patented, high-quality medicines and vaccines available in the U.S. or the European Union on a not-for-profit basis to 1.2 billion people living in 45 lower-income countries around the world. Watch this video to learn more about the Accord and how we’re working together to help strengthen health systems, speed diagnosis and increase access to our patented medicines and vaccines.

Rwanda Receives First Shipment of Pfizer Medicines and Vaccines

1200x800.jpg

The first-ever delivery of nine Pfizer patent-protected medicines and vaccines has been delivered through An Accord for a Healthier World in Rwanda. The shipment included 1,500 treatment packets for life threatening infectious diseases, inflammatory diseases and certain cancers.

“In partnership with Pfizer and ‘An Accord for a Healthier World’, we are proud to provide rapid and affordable access to these Pfizer medicines and vaccines, which have the power to save and improve patient lives all across Rwanda,” said The Minister of Health, Dr. Daniel Ngamije.

Pfizer and the Rwanda Ministry of Health are also providing professional healthcare education and training and are exploring partnerships to support Rwandan medical specialists, diagnostic enhancements and the establishment of a telemedicine consultation platform to connect healthcare professionals in Rwanda with experts around the world.

Explore how An Accord for a Healthier World is working to close the health equity gap.

  • GettyImages-1129628379_900x400_1.jpg

    An Accord for a Healthier World is a first-of-its-kind initiative to enable sustained, equitable access to high-quality, safe, and effective medicines and vaccines with the potential to improve the health of 1.2 billion people living in lower-income countries around the world. 

    Through the Accord, we have committed to provide Pfizer’s patent-protected medicines and vaccines available in the U.S. or European Union on a not-for-profit basis to 45 lower-income countries around the world. By doing so, we aim to provide breakthrough prevention and treatment options for millions of people impacted by deadly infectious diseases like COVID-19 and pneumonia, as well as certain cancers and rare and inflammatory diseases. As we launch new medicines and vaccines, those products will also be included in the Accord portfolio on a not-for-profit basis. 

  • GettyImages-140825889_900x400.jpg

    Half of the world’s population cannot access the healthcare they need, and it can take years longer for medicines to reach people in lower income countries.6,7 The Accord is working to provide lifesaving treatment for diseases that claim the lives of nearly one million people each year and to support better health for at least half a million more suffering from chronic diseases.8

    The patent-protected medicines and vaccines made available through the Accord help to treat and prevent infectious diseases including COVID-19, pneumonia, and meningitis. They help to treat certain cancers including types of leukemia, breast cancer, and advanced kidney cancer. And they manage inflammatory and rare diseases.

  • GettyImages-500871049_900x400.jpg

    Accord partners are working together with Pfizer to identify quick and efficient regulatory pathways and procurement processes to reduce the amount of time it can take to make new medicines and vaccines available in these countries. Additionally, we are working closely with healthcare officials in Rwanda, Ghana, Malawi, Senegal and Uganda to identify opportunities to support improved diagnosis, healthcare professional education, and training, along with supply chain management and other infrastructure enhancements. And we are already making progress – the first lifesaving medicines and vaccines have arrived in Rwanda and new partners are signing on.

  • 85758311_900x400.jpg

    Children in low-income countries are 10 times less likely to reach their fifth birthday compared to those in high-income countries.4 Under the Accord, and with funding from the Bill & Melinda Gates Foundation, Pfizer is advancing the development of vaccine candidates for the prevention of Group B Streptococcus—a leading cause of stillbirth and newborn mortality in low-income countries. Pfizer is also exploring opportunities to support other maternal vaccines, including Respiratory Syncytial Virus (RSV) vaccine development.

    Learn More

Countries in An Accord for a Healthier World

Equity_World_Access_Map_1140x675_CountryList.jpg

Patient incomes shouldn’t affect health outcomes. And geography shouldn’t impact quality of care.

Through this initiative, we have committed to provide all current and future patent-protected Pfizer medicines and vaccines available in the U.S. or European Union on a not-for-profit basis to 45 lower-income countries around the world.

Partners Leading the Way

The Accord partners are calling on global health leaders and organizations to join us to strengthen health systems and speed access to medicines and vaccines that can save and improve lives. Hear from our partners about how we’re working to close the health equity gap for everyone, everywhere.

Bourla_600x400.jpg

Albert Bourla

Chief Executive Officer and Chairman, Pfizer

We are working closely with global health leaders to make improvements in diagnosis, education, infrastructure, storage, and more. Only when all the obstacles are overcome can we end healthcare inequities and deliver for all patients.

/Gates_600x400.jpg

Bill Gates

Co-Chair of the Bill & Melinda Gates Foundation

An Accord for a Healthier World could help millions more people in low-income countries get the tools they need to live a healthy life. Pfizer is setting an example for other companies to follow.

Kagame_600x400.jpg

His Excellency Paul Kagame

President of Rwanda

Combined with additional investments in strengthening Africa’s public health systems and pharmaceutical regulators, the Accord is an important step toward sustainable health security for countries at every income level.

Chakwera_600x400.jpg

His Excellency Lazarus Chakwera

President of Malawi

The great thing about this Accord is that it helps low-income countries without violating their dignity and agency as people, for it is a true partnership that involves both Pfizer and countries like Malawi sharing the burden of costs and tasks in the production and delivery of supplies that will save millions of lives.

  1. Dent J, Graef K, Hargan-Calvopina J, LeJeune A, Seymour D, Weber C. African Access Initiative: A holistic, multi-sector approach to mitigating Africa’s cancer crisis. Journal of Clinical Oncology. 2020;38(15_suppl). doi:10.1200/jco.2020.38.15_suppl.e19015
  2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122505/
  3. https://publichealth.jhu.edu/2018/poverty-increases-risk-of-non-communicable-diseases-in-lower-income-countries
  4. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0253073
  5. https://www.who.int/news/item 13-12-2017-world-bank-and-who-half-the-world-lacks-access-to-essential-health-services-100-million-still-pushed-into-extreme-poverty-because-of-health-expenses #:~:text=At%20least%20half%20of%20the,out%20of%20their%20own%20pockets.
  6. Ahonkhai V, Martins SF, Portet A, Lumpkin M, Hartman D. Speeding access to vaccines and medicines in low- and middle-income countries: A case for change and a framework for Optimized Product Market Authorization. PLOS ONE. 2016;11(11). doi:10.1371/journal.pone.0166515
  7. Internal calculations based on data collected via https://vizhub.healthdata.org/gbd-compare/
  8. https://data.unicef.org/topic/child-survival/under-five-mortality/